Oct 2025 – Mar 2026 | CME/MOC Nationwide Grand Rounds CLL Series
Optimizing Treatment for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
A CME/MOC-Accredited Interactive Grand Rounds Series
Research To Practice (RTP) is pleased to offer community- and academic-based hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on the management of chronic lymphocytic leukemia. Each session in this regional series will feature a blend of didactic presentation, discussion of steering committee members’ treatment recommendations, interactive polling of attendees using keypad devices and follow-up audience Q&A.
If you are interested in hosting a session at your institution, please email our Meeting Services Department at GRTeam@ResearchToPractice.com or call (800) 233-6153.
Event Details
Catherine C Coombs, MD
Associate Clinical Professor
Division of Hematology/Oncology
Department of Medicine
UCI Health
Orange County, California
Matthew S Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology)
Stanford University School of Medicine
Stanford, California
Nicole Lamanna, MD
Judy Horrigan Professor of Medicine
Director of the Chronic Lymphocytic
Leukemia Program
Leukemia Service
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/Columbia University Irving Medical Center
New York, New York
Jeff Sharman, MD
Medical Director of Hematology Research
Sarah Cannon Research Institute at
Willamette Valley Cancer Center
Eugene, Oregon
Jennifer Woyach, MD
Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University
Comprehensive Cancer Center
Columbus, Ohio
Agenda
Each 1-hour session will include 3 topic modules focused on optimizing treatment for patients with relapsed/refractory chronic lymphocytic leukemia. Each event will employ an identical format that will include the following elements:
- Discussion of Steering Committee Members’ Treatment Recommendations
- Review of Available Clinical Research Findings
- Integration of Interactive Audience Polling Result
- Impact of the evolving up-front CLL treatment paradigm on the management of R/R disease
- Clinical and biological factors guiding decision-making for individual patients with R/R CLL
- Long-term follow-up from Phase III trials evaluating covalent BTK inhibitors and Bcl-2 inhibitors for patients with R/R CLL
- Current role of rechallenge with an agent or class of agents received in a prior line of therapy
- Available data sets evaluating covalent BTK inhibitors in combination with venetoclax in R/R CLL
- Mechanistic similarities and differences between noncovalent and covalent BTK inhibitors; implications for efficacy and tolerability
- Extended follow-up from the Phase I/II BRUIN study of pirtobrutinib for patients with R/R CLL
- Published efficacy and safety findings from the Phase III BRUIN CLL-321 trial of pirtobrutinib versus investigator’s choice of idelalisib/rituximab or bendamustine/rituximab for BTK inhibitor-pretreated CLL
- FDA approval and current role of pirtobrutinib in R/R CLL
- Tolerability profile of pirtobrutinib; optimal approaches to monitoring for and managing common toxicities associated with the agent
- Published efficacy and safety findings with lisocabtagene maraleucel (liso-cel) for R/R CLL from the Phase I/II TRANSCEND CLL 004 trial
- FDA approval of liso-cel for CLL previously treated with a BTK inhibitor and a Bcl-2 inhibitor; current clinical role and optimal patient selection
- Potential benefits of clinical trial participation for patients with CLL
- Ongoing Phase III trials (eg, BRUIN CLL-313, BRUIN-CLL-314, BRUIN CLL-322) of pirtobrutinib in earlier settings and/or in combination with other systemic therapies; estimated completion dates
- Rationale for the investigation of bispecific antibodies in patients with R/R CLL; antitumor activity and safety documented with epcoritamab in the Phase Ib/II EPCORE CLL-1 study
- Mechanistic similarities and differences between BTK degraders and BTK inhibitors
- Preliminary safety and efficacy of the BTK degrader BGB-16673 in patients with heavily pretreated CLL in the Phase I CaDAnCe-101 study; FDA fast track designation and potential clinical role
- Other promising agents and strategies under investigation for CLL
Each session will conclude with a 5-minute Q&A segment
CE Information
Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.
Learning Objectives
- Analyze how age, performance status, prior therapeutic exposure, and other biologic and disease related factors impact the selection of therapy for patients who relapse following first-line treatment for chronic lymphocytic leukemia (CLL).
- Appraise the similarities and differences between covalent and noncovalent Bruton’s tyrosine kinase (BTK) inhibitors and recognize the implications for clinical activity and tolerability.
- Discuss available clinical research findings demonstrating the efficacy and safety of noncovalent BTK inhibitors in patients with CLL, and use this information to effectively incorporate these agents into the care of individuals refractory to covalent BTK inhibition and anti-B-cell lymphoma 2 (Bcl-2) therapy.
- Evaluate the biologic rationale for the investigation of CD19-directed chimeric antigen receptor (CAR) T-cell therapy in patients with CLL, and identify appropriate individuals for treatment with this novel therapeutic strategy.
- Appraise clinical investigator best practices for various relapsed/refractory CLL management situations and leverage this information to facilitate improved shared decision-making with your patients.
- Recall available and emerging data with novel agents and combination strategies currently under investigation in CLL and, where applicable, refer eligible patients for clinical trial participation.
CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
These educational activities may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.
Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporter
These activities are supported by an educational grant from Lilly.